U.S. pharma giant copyright scrapped two experimental weight loss tablets past 12 months—a when-each day capsule, lotiglipron, as a result of elevated liver enzymes as well as a twice-day-to-day pill, danuglipron, as a result of powerful Unwanted effects—but CEO Albert Bourla has stated the company is set to “Engage in and gain” in the bein